Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
复制标题
DOI：
10.1371/journal.pone.0201906
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Hwang JS
中科院分区：
文献类型：
--
作者：
Lee HS;Yoon JS;Park KJ;Hwang JS
促性腺激素释放激素激动剂(GnRHa)是治疗中枢性性早熟(CPP)的首选药物，已被广泛应用数十年。我们确定了GnRHa治疗对患有特发性CPP的女孩的生殖结局的影响。这项研究包括84名达到成年身高的每月接受醋酸亮丙瑞林治疗的女孩。我们将他们的最终成年身高(FAH)与最初预测的成年身高(PAH)进行了比较。我们对所有被诊断为CPP的女孩进行了与FAH相关的因素的多变量分析。我们在平均治疗时间2.98±0.73年(1.5-4.8年)后进行最终评估，平均年龄14.1±0.8年。初潮年龄12.6±0.6岁，停药后16.5±6.1个月。FAH平均值为160.1±5.0cm.显著高于起始值(156.1±5.7cm.p<；0.001)。为了研究初治年龄对生长发育的影响，我们将所有患者分为6~8岁治疗组(n=23)和8年后治疗组(n=61)，两组间FAH无显著差异。FAH与治疗结束时的身高标准差(SDS)和靶身高呈显著正相关，而治疗开始和结束时骨龄与年龄的差值与FAH呈负相关。接受GnRHa治疗的CPP女孩的FAH显著高于治疗前的PAH。此外，GnRHa治疗对患有CPP的女孩即使在8岁后仍然有效。
Gonadotropin-releasing hormone agonists (GnRHa) are the treatment of choice for central precocious puberty (CPP) and have been widely used for several decades. We determined the effect of GnRHa treatment on the auxological outcomes of girls with idiopathic CPP. This study included 84 girls treated monthly with depot leuprolide acetate who had reached adult height. We compared their final adult height (FAH) with their initial predicted adult height (PAH). We performed a multivariate analysis of the factors associated with FAH on all girls diagnosed with CPP. We performed the final evaluations at a mean age of 14.1 ± 0.8 years after a mean treatment duration of 2.98 ± 0.73 years (ranging from 1.5–4.8 years). Menarche had occurred at 12.6 ± 0.6 years of age, which was 16.5 ± 6.1 months after discontinuation of GnRHa therapy. Mean FAH was 160.1 ± 5.0 cm, which was significantly higher than the initial PAH (156.1 ± 5.7 cm; P < 0.001). To investigate whether growth outcomes were influenced by the age at initial treatment, we divided all patients into two groups, those treated between 6 and 8 years (n = 23) and those treated after 8 years (n = 61); no significant differences were observed in FAH between the two groups. FAH was significantly and positively correlated with the height standard deviation score (SDS) at the end of treatment and with the target height, whereas the difference between bone age and chronological age at the start and end of treatment was negatively correlated with FAH. FAH was significantly higher than the initial PAH in girls with CPP who were treated with GnRHa. Also, GnRHa treatment was still effective even after 8 years of age in girls with CPP.
登录
查看更多内容
影响因子：
5.8
作者：
Heger, S;Partsch, CJ;Sippell, WG
通讯作者：
Sippell, WG
DOI：
10.2165/00148581-200406040-00002
发表时间：
2004-01-01
期刊：
Paediatric drugs
影响因子：
--
作者：
Antoniazzi, Franco;Zamboni, Giorgio
通讯作者：
Zamboni, Giorgio
影响因子：
5.8
作者：
Brito, Vinicius Nahime;Latronico, Ana Claudia;Mendonca, Berenice Bilharinho
通讯作者：
Mendonca, Berenice Bilharinho
DOI：
10.1186/1687-9856-2011-7
发表时间：
2011
期刊：
International journal of pediatric endocrinology
影响因子：
--
作者：
Lee PA;Neely EK;Fuqua J;Yang D;Larsen LM;Mattia-Goldberg C;Chwalisz K
通讯作者：
Chwalisz K
影响因子：
2.2
作者：
Park J;Hwang TH;Kim YD;Han HS
通讯作者：
Han HS